Cargando…

Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse

Shedding of cancer cells from the primary site or undetectable bone marrow region into the circulatory system, resulting in clinically overt metastasis or dissemination, is the hallmark of unfavorable invasive cancers. The shed cells remain in circulation until they extravasate to form a secondary m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chelakkot, Chaithanya, Yang, Hobin, Shin, Young Kee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8781286/ https://www.ncbi.nlm.nih.gov/pubmed/35056131 http://dx.doi.org/10.3390/ph15010075

Ejemplares similares

Modulating Glycolysis to Improve Cancer Therapy
por: Chelakkot, Chaithanya, et al.
Publicado: (2023)

SMAD4 Controls Cancer Cell Metabolism by Regulating Methylmalonic Aciduria Cobalamin Deficiency (cbl) B Type
por: Song, Kyoung, et al.
Publicado: (2022)

Selection Strategies and Practical Application of BRAF V600E-Mutated Non–Small Cell Lung Carcinoma
por: Hwang, Inwoo, et al.
Publicado: (2022)

An Immune–Magnetophoretic Device for the Selective and Precise Enrichment of Circulating Tumor Cells from Whole Blood
por: Chelakkot, Chaithanya, et al.
Publicado: (2020)

Macrosphelide A Exhibits a Specific Anti-Cancer Effect by Simultaneously Inactivating ENO1, ALDOA, and FH
por: Song, Kyoung, et al.
Publicado: (2021)

Mechanisms regulating intestinal barrier integrity and its pathological implications
por: Chelakkot, Chaithanya, et al.
Publicado: (2018)

Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors
por: Mekonnen, Negesse, et al.
Publicado: (2022)

Microfluidic Chip-Based Cancer Diagnosis and Prediction of Relapse by Detecting Circulating Tumor Cells and Circulating Cancer Stem Cells
por: Cho, Hyeon-Yeol, et al.
Publicado: (2021)

Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer
por: Zhao, Ren, et al.
Publicado: (2016)

Comparison of RNA Marker Panels for Circulating Tumor Cells and Evaluation of Their Prognostic Relevance in Breast Cancer
por: Welsch, Eva, et al.
Publicado: (2023)

Intestinal Epithelial Cell-Specific Deletion of PLD2 Alleviates DSS-Induced Colitis by Regulating Occludin
por: Chelakkot, Chaithanya, et al.
Publicado: (2017)

Circulating Tumor DNA–Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas
por: Kim, Seok Jin, et al.
Publicado: (2023)

Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer
por: Hu, Wenwei, et al.
Publicado: (2017)

Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management
por: Cieślikowski, Wojciech A., et al.
Publicado: (2021)

Effect of HPV E6/E7 siRNA with Chemotherapeutic Agents on the Regulation of TP53/E2F Dynamic Behavior for Cell Fate Decisions
por: Rajasekaran, Nirmal, et al.
Publicado: (2017)

Clinical relevance and biology of circulating tumor cells
por: Bednarz-Knoll, Natalia, et al.
Publicado: (2011)

Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer
por: Papadaki, Maria A., et al.
Publicado: (2020)

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse
por: Saloustros, Emmanouil, et al.
Publicado: (2011)

Late relapsing germ cell tumors with elevated tumor markers
por: Che, Yue, et al.
Publicado: (2021)

Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer
por: Li, Yang, et al.
Publicado: (2019)

Heterogeneity in Circulating Tumor Cells: The Relevance of the Stem-Cell Subset
por: Agnoletto, Chiara, et al.
Publicado: (2019)

Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia
por: Yoon, Jae-Ho, et al.
Publicado: (2019)

Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer
por: Jeannot, Emmanuelle, et al.
Publicado: (2021)

Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2020)

Circulating tumor cells and neutrophil-lymphocyte ratio are predictive markers for metastatic colorectal cancer patients
por: Li, Heming, et al.
Publicado: (2021)

Circulating Tumor Cells Enumerated by a Centrifugal Microfluidic Device as a Predictive Marker for Monitoring Ovarian Cancer Treatment: A Pilot Study
por: Kim, Hyera, et al.
Publicado: (2020)

Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers
por: Yang, Xin, et al.
Publicado: (2022)

RGS2-mediated translational control mediates cancer cell dormancy and tumor relapse
por: Cho, Jaebeom, et al.
Publicado: (2023)

The Value of Circulating Tumor Cells and Tumor Markers Detection in Lung Cancer Diagnosis
por: Guo, Sumin, et al.
Publicado: (2023)

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer
por: Heidrich, Isabel, et al.
Publicado: (2021)

Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer
por: Rose-James, Alphy, et al.
Publicado: (2012)

Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors
por: Ravegnini, Gloria, et al.
Publicado: (2019)

Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer
por: Won, Eun Jeong, et al.
Publicado: (2016)

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer
por: Varkaris, Andreas, et al.
Publicado: (2019)

Classification of Circulating Tumor Cells by Epithelial-Mesenchymal Transition Markers
por: Wu, Shiyang, et al.
Publicado: (2015)

Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer
por: Lohmann, Ana Elisa, et al.
Publicado: (2018)

Circulating tumor cells as a prognostic and predictive marker in gastrointestinal stromal tumors: a prospective study
por: Li, Qiang, et al.
Publicado: (2016)

Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer
por: Fryczkowski, M., et al.
Publicado: (2018)

Clinical relevance of the combined analysis of circulating tumor cells and anti-tumor T-cell immunity in metastatic breast cancer patients
por: Muraro, Elena, et al.
Publicado: (2022)

Epithelial-mesenchymal transition status of circulating tumor cells in breast cancer and its clinical relevance
por: Zhou, Jiaojiao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nqpn2egm3uvaobieton7evdp4s